Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–2792., , .
Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–136., .
Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71:606–614., , .
National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer. 1994;73:377–383., , .
Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 2004;49: 77–86., .
Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96., , .
SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008., , .
The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001;82:223–228., , .
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24:863–871., , .
Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med. 2002;346: 1660–1662.
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26: 1331–1337., , .
Advanced ovarian cancer. Curr Treat Options Oncol. 2000;1:139–146., .
Gynecologic malignancies in older women. Oncology. 2001;15:580–586; discussion 592–594, 597–598., , .
Ovarian cancer in elderly women. Oncology. 2003;17:1075–1081; discussion 1081, 1085–1086, 1091., .
Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007;109:1053–1061., , .
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–3627., , .
Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstet Gynecol. 2003;102:156–161., , .
Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95: 1314–1320., , .
Impact of age on survival of patients with ovarian cancer. Gynecol Oncol. 1993;49:236–239., , .
Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol. 2004;13:181–186., , .
Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008; 18(4):660–669., , .
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer. 2007;17: 1003–1010., , .
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259., , .
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2006;100:300–307., , .
Treatment patterns by decade of life in elderly women (> or = 70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98:403–408., , .
Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol. 2004;190:1398–1400., , .
Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193: 2077–2082., , .
Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106:381–387., , .
Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol. 2002;86:274–278., , .
Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol. 2001;81:447–455., , .
Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol. 1999;73: 137–139., , .
Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol. 1999;75:437–443., , .
Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99:352–357., , .
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6., , .
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21: 3194–3200., , .
The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97:104–109., , .
Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004;94:540–549., , .
Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173–178., , .
Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer. 2000;36:817–820., .
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008:66(3):229–236., , .
Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d';Investigateurs Nationaux pour l';Etude des Cancers Ovariens. Ann Oncol. 2007;18: 256–262., , .
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008., , .
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360: 505–515.ON:
Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol. 2002;86:316–322., , .
Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol. 2002;85:445–450., , .
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335: 1950–1955., , .
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19: 1001–1007., , .
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43., , .
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:437–443., , .
Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–659., , .
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol. 2007;18:1314–1321., , .
Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110:1376–1384., , .
International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34., , .
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006;24:1846–1851., , .
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J Clin Oncol. 2007;25: 1832–1843., , .
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106., , .
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707., , .
The management of recurrent ovarian cancer. Semin Oncol. 2007;34:S1–S15., , .
Lung cancer in the elderly. J Clin Oncol. 2007;25: 1898–1907., , .
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8:1101–1115., , .
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer. 2002;94:1961–1967., , .
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8., , .
Weekly topotecan in the management of ovarian cancer. Gynecol Oncol. 2003;90: S34–S38.
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009;27:199–205., , .
Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902–2908.
Resource utilization for ovarian cancer patients at the end of life: how much is too much?Gynecol Oncol. 2005;99:261–266., , .
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc. 2007;55:1604–1608., , .
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795–1800., , .
The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579., , .
Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98:521–529., , .
Quality of life in ovarian cancer patients during chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:S28–S29., , .
Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103:120–126., , .
Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group phase II study (E2E93). J Cancer. 2001;7:155–164., , .
Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004;22:4595–4603., , .
An analysis of the impact of demographic, clinical and social factors on health related quality of life. Value Health. 1999;2:308–318., , .
Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys. 2006;65: 830–835., , .
Baseline characteristics influencing quality of life in gynecologic cancer. Health Qual Life Outcomes. 2007;5:25–32., , .
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?J Clin Oncol. 2008;26:3860–3866., , .
Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer. 2008;112(10):2221–2227., , .
Combination of endometrial thickness and time since menopause in predicting endometrial cancer in women with postmenopausal bleeding. J Clin Ultrasound. 2004;32(5):219–224., , .
The relation between age, time since menopause, and endometrial cancer in women with postmenopausal bleeding. Int J Gynecol Cancer. 2007;17(5):1118–1123., , .
Age related trends in the incidence of endometrial cancer in South East England 1962–1997. J Obstet Gynaecol. 2005;25(1):35–38., , .
Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case-control family study of older women. Cancer. 1999;85(11):2444–2449., , .
Age-specific survival of women with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2000;79(1):86–89., , .
Trends in the demographics and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198(218): E1–E6., , .
Gynecologic Oncology Group. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008;112(10):2202–2210., , .
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638., , .
The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992–2002. Gynecol Oncol. 2008;111(1):35–40., , .
Treatment toxicity, disease recurrence and survival as related to obesity in women with early endometrial carcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107:2786–2791., , .
Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998;71(3):340–343., , .
Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol. 2001;97(5 Pt 1):707–711., , .
Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Gynecol Oncol. 2005;96(2):362–367., , .
The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 2000;48(3):779–790., , .
Total laparoscopic hysterectomy versus laparoscopic-assisted vaginal hysterectomy in endometrial cancer: surgical and survival outcomes. J Min Inv Gynecol. 2009;16(3):333–339., , .
What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman?Gynecol Oncol. 2008;111(1):41–45., , .
A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008;199:360–362., , .
Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol. 2008;112:1207–1213., , .
The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101(3): 470–475., , .
The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol. 2005;28(2):157–164., , .
Is endometrial carcinoma intrinsically more aggressive in elderly patients?Cancer. 2003;98(11):2368–2377., , .
The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006;103(1):87–93., , .
Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22(7):1234–1241., , .
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–1411., , .
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–751., , .
Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys. 2004;59(5):1432–1438., , .
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;62(1):111–117., , .
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007;25(20):2983–2990.
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007;107(2):285–291., , .
Rare Cancer Network. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol. 2008;108(2):298–305., , .
Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24(1):36–44., , .
The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc. 2004;52(11):1907–1912., , .
Impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol. 2005;193:1369–1375., , .
The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2003;90: 150–157., , .
Psychosocial status in chronic illness: a comparative analysis of six diagnostic groups. N Engl J Med. 1984;311(8):506–511., , .
Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: a randomized trial. Gynecol Oncol. 2008;109(1):19–26., , .
Impact of overweight and obesity on health-related quality of life: a Swedish population study. Int J Obes Relat Metab Disord. 2002;26(3):417–424., , .
Relation between body weight and health-related quality of life among the elderly in Spain. Int J Obes. 2003;27:701–709., , .
Body mass index and physical function in older women. Obes Res. 2002;10:740–747., , .
Obesity and physical and emotional well-being: associations between body mass index, chronic illness and the physical and mental components of the SF-36 questionnaire. Obes Res. 2000;8(2):160–170., , .
Impact of weight loss on health-related quality of life. Qual Life Res. 1999;8:275–277., , .
Health-related quality of life in physically active and sedentary obese women. Am J Hum Biol. 2002;14:777–785., , .
Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes. 2003;27:1227–1232., , .
Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer. 2002;87:178–184., , .
Quality of life after treatment for gynecologic malignancies: a pilot study in an outpatient clinic. Gynecol Oncol. 2002;87(2):178–184., , .
A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol Oncol. 2001;83(1):10–19., , .
Health-related quality of life of patients with endometrial cancer who are disease-free following external irradiation. Acta Oncol. 2001;40(7):816–824., .
Quality of life in endometrial cancer survivors. Maturitas. 1999;31(3):227–236., , .
Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys. 2007;69(1):125–132., , .
Cancer survivors'; adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol. 2008;26(13):2198–2204., , .
An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;94:368–374., , .